



Statement on Due Diligence Processes Covering Child Labour Risks

For the year ending 31 December 2023

AstraZeneca's Commitment to Human Rights

This statement targeting child labour due diligence has been developed in accordance with art. 964j-k of the Swiss Code of Obligations and the Ordinance on Due Diligence and Transparency in relation to Minerals and Metals from Conflict-Affected Areas and Child Labor.

AstraZeneca does not tolerate modern slavery including child labour in any part of our business or our supply chains. The AstraZeneca Human Rights Statement asserts our responsibility to respect the rights of all people.

This commitment to respecting human rights is underpinned in our policies, our values and in our relationships with third parties. Our [Code of Ethics](#) defines our values at work and guides our behaviours. It contains a requirement for our employees to interact with others in an ethical and proper manner and highlights our employment principles and other ethical standards. It specifically prohibits the use of modern slavery or human trafficking in our business. The AstraZeneca [Expectations of Third Parties policy informs our](#) third parties that we do not tolerate the use of child labour and forced labour by third parties.

The Global Risk Owner for modern slavery and human trafficking is the Executive Vice-President Operations & Information Technology, Chief Sustainability Officer. Their remit includes accountability for our Global Supply Chain & Strategy and Global Procurement functions. To support the Executive Vice-President, we have dedicated internal compliance and audit resources responsible for reviewing the manner in which we manage all forms of risk, including human & labour rights which covers modern slavery including child labour.

[AstraZeneca's Modern Slavery Statement](#) outlines our approach to identifying and addressing risks of modern slavery including child labour in our business operations and supply chain globally. AstraZeneca supports and adheres to the principles set out in the UN Declaration of Human Rights, and our employment policies detail our high standards of employment practice. These internal policies and practices include respecting diversity and, as a minimum, complying with national legal requirements regarding wages and working hours. We also support the International Labour Organisation's standards regarding child labour and minimum working age.

Our standards comply with all current national and international laws, regulations, and codes to prevent trafficking and slavery in our own business operations. Further, we require our contracting partners and those companies within our supply chain to do the same, as set out in our Global Standard on Expectations of Third Parties. We hold third parties to high standards whilst offering

opportunities to build their own sustainability knowledge and capabilities.

Risk Management

We require our suppliers and other third parties to operate in line with internationally recognised human rights and promote and maintain a culture of respect and equal opportunities. This requires that our suppliers and other third parties do not use any form of forced, bonded, involuntary or indentured labour.

AstraZeneca has a Third Party Risk Management (3PRM) process in place to identify and assess potential risks connected with our suppliers, which includes human and labour rights as a standalone risk area and assesses risks such as child labour. The company's expectations of third parties, requires the third parties we work with to ensure there is no use of child labour in their organisation, and includes requirements for prompt reporting of concerns related to modern slavery and human trafficking.

We conduct an internal labour rights survey every two years in the countries where we operate focused on the ILO's core themes. This survey helps us to identify and address any potential local gaps as well as areas of best practice.

Our Grievance Mechanism

We have an established process and affiliated systems in place for employees to raise concerns and to protect whistle-blowers from retaliation and identification. We encourage anyone to report in good faith any concerns regarding slavery and human trafficking, as well as any other compliance risks. Whistle-blowers can choose to report anonymously at www.AZethics.com. AstraZeneca takes any such reports seriously and investigates all concerns raised, seeking to resolve matters in accordance with our Code of Ethics and applicable law.

The AstraZeneca Modern Slavery Statement 2023 can be viewed via the following link.

https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/Modern_Slavery_Act_Statement.pdf

AstraZeneca in Switzerland

AstraZeneca AG is a British pharmaceutical company that has been operating in Switzerland for almost 50 years. We are one of the highest revenue pharmaceutical companies in Switzerland and operate in the following therapeutic areas: oncology, respiratory diseases and immunology, cardiovascular, renal and metabolic disorders plus vaccines and immunotherapies, which also includes medicines for the control of COVID-19. We do not operate any manufacturing operations in Switzerland; our medicines are supplied from various AstraZeneca sites around the world, primarily UK, Sweden, France and US.

The primary aim of our 284 employees in Switzerland is to make new medicines available to affected patients as quickly as possible. In Switzerland, more than 230,000 people are treated with a drug from AstraZeneca. We expect over 35 new therapies to be authorised by 2026. Further information about AstraZeneca Switzerland: <https://www.astrazeneca.ch/en>

Final remarks

AstraZeneca AG, as part of the larger organization, aligns to the policies referred to in this statement and ensures compliance within its operations and with its third-party relationships.

During the business year of 2023, we deem the due diligence performed sufficient to mitigate risks of child labour in AstraZeneca AG. No indications of child labour were observed during the reporting year.

This statement has been approved by the AstraZeneca AG Board of Directors.
Date: 28 June 2024